Commentary on Parker and Weir.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Systematic review of available software for multi-arm multi-stage and platform clinical trial design.Trials · 2021
   Pooled it
2. Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: Clear guidance is needed.Contemporary clinical trials · 2022
   Trial
3. When to adjust for multiplicity in cancer clinical trials.Journal of the National Cancer Institute. Monographs · 2025
   Article
4. Online error rate control for platform trials.Statistics in medicine · 2023
   Article
5. Online control of the False Discovery Rate in group-sequential platform trials.Statistical methods in medical research · 2022
   Article
6. Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials.Pharmaceutical statistics · 2022
   Article
7. Multiple secondary outcome analyses: precise interpretation is important.Trials · 2022
   Article
8. Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials.Therapeutic innovation & regulatory science · 2021
   Review
9. Data monitoring committees for clinical trials evaluating treatments of COVID-19.Contemporary clinical trials · 2020
   Article
10. Design Considerations for a Phase II Platform Trial in Major Depressive Disorder.Pharmaceutical statistics
    Article

Corrections and comments

• Comment on
  Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification.2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.